{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

7_Ghostwriting - Ross


Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
8 manuscripts related to rofecoxib that the company was preparing, includ- ing intended titles, authors, and jour- nals. 42 Review articles were identified by 7 of the 8 investigators listed in Fig- ure 4, several with titles nearly exactly as proposed. 43-49 In addition, FIGURE 5 displays a contract for Health Science Communications Inc to provide a 20-page review manuscript with 6 fig- ures or tables intended for a cardiol- ogy audience for Merck at a cost of $23 841.00. 50 Contracts also were iden- tified between these 2 parties to pro- vide review manuscripts intended for nephrology and primary care audi- ences, 51,52 as well as for other medical specialties. Health Science Communi- cations Inc describes itself on its Web site as “a full-service health mar- keting communications company committed to the highest quality of service. .. We’re there pre-launch, pre- paring the market for a product’s in- troduction. At launch, we establish the foundation for product uptake.” 53
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.
  • Spring '10
  • McGrand
  • Rofecoxib, Scientific Therapeutics Information, Health Science Communications Inc, Dr. William Garnett, Health Science Communications

{[ snackBarMessage ]}

Ask a homework question - tutors are online